Impaired Coagulation in Early RA Improved by Antirheumatic Therapy
Study Overview
This study looks at how treatment affects blood clotting in patients newly diagnosed with rheumatoid arthritis (RA).
Key Findings
- Patient Treatment: Patients started on methotrexate and were randomly assigned to receive either additional conventional treatment, certolizumab pegol, abatacept, or tocilizumab.
- Biomarkers Analyzed: Various blood markers related to clotting were measured at the start of treatment, and again at 12 and 24 weeks.
Results Summary
At the start, patients showed high levels of several clotting markers. After 24 weeks of treatment:
- Significant decreases were observed in F1+2, fibrinogen, D-dimer, overall haemostatic potential (OHP), and other markers.
- Tocilizumab showed the greatest impact, reducing OHP by 73%, compared to other treatments.
Conclusion
Patients with newly diagnosed RA had active clotting issues, which improved with effective treatments, especially with tocilizumab.
Enhancing Clinical Trials and Patient Care
Clinical trials are essential in creating safe and effective medical treatments. We must integrate these findings into regular healthcare practice.
Introducing DocSym
DocSym, our AI-powered platform, brings together ICD-11 standards, clinical protocols, and research into one easy-to-use resource for healthcare providers.
Streamlining Healthcare Operations
In today’s medical field, efficiency is vital. Our mobile applications assist with:
- Scheduling appointments
- Monitoring treatments
- Facilitating telemedicine
Benefits of AI in Clinics
Implementing AI helps clinics improve workflow, enhance patient care, and reduce paperwork. Discover more about our solutions at aidevmd.com.
